ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Neuronetics Inc

Neuronetics Inc (STIM)

1.46
0.13
(9.77%)
Closed December 24 4:00PM
1.46
0.00
(0.00%)
After Hours: 4:45PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.46
Bid
1.43
Ask
1.46
Volume
198,257
1.25 Day's Range 1.475
0.52 52 Week Range 5.0699
Market Cap
Previous Close
1.33
Open
1.32
Last Trade
10
@
1.46
Last Trade Time
Financial Volume
$ 274,818
VWAP
1.3862
Average Volume (3m)
416,749
Shares Outstanding
30,347,504
Dividend Yield
-
PE Ratio
-1.47
Earnings Per Share (EPS)
-0.99
Revenue
71.35M
Net Profit
-30.19M

About Neuronetics Inc

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-sy... Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
-
Neuronetics Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker STIM. The last closing price for Neuronetics was $1.33. Over the last year, Neuronetics shares have traded in a share price range of $ 0.52 to $ 5.0699.

Neuronetics currently has 30,347,504 shares outstanding. The market capitalization of Neuronetics is $40.36 million. Neuronetics has a price to earnings ratio (PE ratio) of -1.47.

STIM Latest News

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the โ€œCompanyโ€) today announced the granting of inducement awards to a new employee as described below. In...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the โ€œCompanyโ€) today announced the granting of inducement awards to new employees as described below. In...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.3632.72727272731.11.581.12892961.34076607CS
40.485249.77431267950.97481.580.91582420621.19652902CS
120.689389.43817308940.77071.580.524167490.8767577CS
26-0.35-19.33701657461.812.050.524037260.93580031CS
52-1.4-48.9510489512.865.06990.522927231.61726145CS
156-3.13-68.19172113294.596.930.522635422.81734715CS
260-3.06-67.69911504424.5222.430.523388275.29349928CS

STIM - Frequently Asked Questions (FAQ)

What is the current Neuronetics share price?
The current share price of Neuronetics is $ 1.46
How many Neuronetics shares are in issue?
Neuronetics has 30,347,504 shares in issue
What is the market cap of Neuronetics?
The market capitalisation of Neuronetics is USD 40.36M
What is the 1 year trading range for Neuronetics share price?
Neuronetics has traded in the range of $ 0.52 to $ 5.0699 during the past year
What is the PE ratio of Neuronetics?
The price to earnings ratio of Neuronetics is -1.47
What is the cash to sales ratio of Neuronetics?
The cash to sales ratio of Neuronetics is 0.62
What is the reporting currency for Neuronetics?
Neuronetics reports financial results in USD
What is the latest annual turnover for Neuronetics?
The latest annual turnover of Neuronetics is USD 71.35M
What is the latest annual profit for Neuronetics?
The latest annual profit of Neuronetics is USD -30.19M
What is the registered address of Neuronetics?
The registered address for Neuronetics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Neuronetics website address?
The website address for Neuronetics is www.neurostar.com
Which industry sector does Neuronetics operate in?
Neuronetics operates in the SURGICAL,MED INSTR,APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BAOSBaosheng Media Group Holdings Ltd
$ 7.10
(310.40%)
58.74M
HOURHour Loop Inc
$ 4.40
(207.69%)
97.42M
GTIGraphjet Technology
$ 0.61
(168.72%)
265.48M
CREVCarbon Revolution Public Ltd
$ 9.16
(135.48%)
26.95M
AVGRAvinger Inc
$ 1.45
(125.72%)
107.53M
SLGLSol Gel Technologies Ltd
$ 0.9798
(-40.62%)
3.07M
DRCTDirect Digital Holdings Inc
$ 3.71
(-32.55%)
23.82M
CHEKCheck Cap Ltd
$ 1.55
(-31.11%)
3.49M
SYTASiyata Mobile Inc
$ 0.5178
(-30.83%)
2.63M
BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF
$ 15.47
(-30.38%)
147.98k
SVMHSRIVARU Holding Ltd
$ 0.0338
(20.71%)
280.27M
GTIGraphjet Technology
$ 0.61
(168.72%)
265.48M
LITMSnow Lake Resources Ltd
$ 0.5849
(52.84%)
181.22M
LCIDLucid Group Inc
$ 3.20
(3.23%)
108.75M
RGTIRigetti Computing Inc
$ 11.35
(3.56%)
108.38M

STIM Discussion

View Posts
Monksdream Monksdream 6 months ago
STIM under $3
๐Ÿ‘๏ธ0
Dubster watching Dubster watching 8 months ago
Going to do it again!
๐Ÿ‘๏ธ0
Dubster watching Dubster watching 8 months ago
Got 6% 2 hours
๐Ÿ‘๏ธ0
Dubster watching Dubster watching 8 months ago
Momentum play!
๐Ÿ‘๏ธ0
Monksdream Monksdream 10 months ago
STIM 10Q due March 5
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 year ago
STIM new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 year ago
STIM new 52 week low
๐Ÿ‘๏ธ0
AJ Freely AJ Freely 1 year ago
$STIM - 👆Up 6.8% Pre-Market/ Current Price $2.06
Reports Record Q2 '23 Financial & Operating Results
👉Q2 '23 revenue of $17.6m, an increase of 8% over the Q2 '22
👉U.S. treatment session revenue increased 9% over the Q2 of '22
👉Shipped 54 NeuroStar systems
๐Ÿ‘๏ธ0
luckydude777 luckydude777 2 years ago
Slowly moving UP. VERY INTERESTED in their technology. In time, we may be looking at a very LUCRATIVE company here.

We'll see ...
๐Ÿ‘๏ธ0
luckydude777 luckydude777 2 years ago
Wow - after hours filled the gap in ONE day. Very interesting ...
๐Ÿ‘๏ธ0
luckydude777 luckydude777 2 years ago
How big of a deal do you think today's news IS?
๐Ÿ‘๏ธ0
subslover subslover 2 years ago
NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Anxious Depression
July 19 2022 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, including drug-resistant depression and obsessive-compulsive disorder (OCD), announced clearance from the U.S. Food and Drug Administration (FDA) for a new indication for its transcranial magnetic stimulation (TMS) system โ€“ NeuroStar Advanced Therapy for Mental Health โ€“ to treat anxiety symptoms for adult patients who suffer from major depressive disorder (MDD), also known as anxious depression.
โ€œToday, we celebrate a big win for NeuroStar patients and providers,โ€ said Keith J. Sullivan, President and CEO of Neuronetics Inc. โ€œMany people suffering from MDD also experience anxiety symptoms, and these patients with anxious depression are more likely to be severely depressed and to have more thoughts of suicide. This new indication means providers can now describe to MDD patients the benefit of NeuroStar for improving their anxiety symptoms.โ€

NeuroStar is the leader in patient-focused TMS therapy having treated over 134,000 patients who completed more than 4.8 million treatment sessions. The FDA accepted Neuroneticsโ€™ use of real-world data analyzed from NeuroStarโ€™s proprietary TrakStar® platform in granting clearance for this new indication. The TrakStar database contains digital data from patients treated with NeuroStar at over 1,000 centers. Real-world data from TrakStar is particularly valuable because it provides a large sample from a diverse patient group being treated in a clinical practice setting.

โ€œWe would like to acknowledge the contributions of healthcare providers across the country who have partnered with us to help build the worldโ€™s largest database of depression outcomes,โ€ said Cory Anderson, VP R&D and Clinical. โ€œNot only do we have MDD outcomes, but we also receive data on anxiety outcomes from patients with anxious depression, and these real-world results in anxious depression were an important piece of the FDA clearance.โ€

The TrakStar results from 664 anxious depression patients demonstrated that 65.5% achieved a clinically meaningful response which exceeded the pre-established overall study success criteria of a minimum 50% response rate (p<0.0001) and indicated a large treatment effect size of 1.4.

โ€œA clinical presentation of anxiety symptoms in patients with MDD is typically more complex to successfully treat with currently available medications,โ€ said Melissa Fickey, MD, founder of Embracing Life Wellness Center. โ€œNeuroStar has presented a robust data set from over 1,300 patients showing safety and efficacy in relieving both depression and anxiety symptoms in patients with anxious depression.โ€

DASH, TouchStarโ„ข, and standard MDD protocols offered by NeuroStar are all now indicated to treat depression with comorbid anxiety. This clearance closely follows after NeuroStarโ€™s announcement of an obsessive compulsive disorder (OCD) indication, which received FDA clearance in May of this year. For more information about NeuroStar Advanced Therapy for Mental Health, please visit neurostar.com

About Anxious Depression
Major depressive disorder (MDD) is a common and serious psychiatric diagnosis among adults with an estimated prevalence of 13.9M patients under treatment in the United States. Anxiety symptoms are a common co-morbidity in patients with MDD, commonly called anxious depression, with an estimated prevalence of more than 50% of MDD patients. The NeuroStar Advanced Therapy System is now indicated for treating anxiety symptoms for those who may exhibit comorbid anxiety and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasnโ€™t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decre
๐Ÿ‘๏ธ0
urge2surge urge2surge 3 years ago
Guess we got a dog pile here..
๐Ÿ‘๏ธ0
oxnous oxnous 3 years ago
UGLY day


๐Ÿ‘๏ธ0
urge2surge urge2surge 4 years ago
Thank you I'll take a look. Yes it works. If they announce trials on Alzheimer's, who knows where this goes. As it is this is a solid growth company. I was surprised at the secondary offering in light of their revenues.
As for BWAY, the only negative off the cuff is that it is an Israeli company. Tend to be big sink holes...
๐Ÿ‘๏ธ0
EarthBard EarthBard 4 years ago
Brains at (BWAY) is the only other company I know.

My son is an rTMS tech and tells me flat out that it works.

EB
๐Ÿ‘๏ธ0
urge2surge urge2surge 4 years ago
This is a major winning technology an stock, and the board is dead??????
๐Ÿ‘๏ธ0
urge2surge urge2surge 4 years ago
Looking at a solid and easy 100 dollar stock here. The treatments work!!!!
๐Ÿ‘๏ธ0
urge2surge urge2surge 4 years ago
Are their any other public companies in this sector?
Thanks in advance
๐Ÿ‘๏ธ0
TFMG TFMG 4 years ago
$STIM | #Neuronetics Inc +60% Potential Upside


Neuronetics , Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS , a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
Average Analysts Recommendation: BUY
Average Target Price: $5.75




๐Ÿ‘๏ธ0
wesley_ wesley_ 4 years ago
$4.64
๐Ÿ‘๏ธ0
wesley_ wesley_ 4 years ago
$3.96
๐Ÿ‘๏ธ0
wesley_ wesley_ 4 years ago
$3.85
๐Ÿ‘๏ธ0
wesley_ wesley_ 4 years ago
$3.44 lovely
๐Ÿ‘๏ธ0
ClayTrader ClayTrader 4 years ago
* * $STIM Video Chart 07-15-2020 * *

Link to Video - click here to watch the technical chart video

๐Ÿ‘๏ธ0
wesley_ wesley_ 4 years ago
creeping back up HOD for next leg up :)
๐Ÿ‘๏ธ0
wesley_ wesley_ 4 years ago
$3+ surge lovely
๐Ÿ‘๏ธ0
wesley_ wesley_ 4 years ago
$2.88 nice
๐Ÿ‘๏ธ0
ClayTrader ClayTrader 5 years ago
* * $STIM Video Chart 06-23-2020 * *

Link to Video - click here to watch the technical chart video

๐Ÿ‘๏ธ0
instock58 instock58 5 years ago
STIM Up 18.8% , UP 2,87 In AH so far. Slowly rising. Healthcare stocks HOT today...


$STIM should have a strong Open and pre market Wednesday ...especially if price keeps rising in AH,
Closed 2.09
Current 2.16
๐Ÿ‘๏ธ0
CA CHASE CA CHASE 5 years ago
$STIM ADDING BELOW $2.15 FOR ROUND #2 ^
๐Ÿ‘๏ธ0
CA CHASE CA CHASE 5 years ago
$STIM BELOW $2.20 DIP & RIP END OF DAY ^
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 5 years ago
Neuronetics, Inc. is commercial-stage medical technology company. The Company is focused on the design and development of medical devices to treat psychiatric disorders. The Companyโ€™s principal product is NeuroStar Advanced Therapy System. It is a non-invasive treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed magnetic field to induce electrical pulses for stimulating certain areas of the brain associated with mood. The system is used to treat adult patients with major depressive disorders. The Company offers its therapy systems to psychiatrist offices in the United States.
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock